Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 731 | 7.395 |
09:41 ET | 100 | 7.44 |
09:45 ET | 7679 | 7.45 |
09:48 ET | 284 | 7.445 |
09:50 ET | 200 | 7.44 |
09:52 ET | 278 | 7.4 |
09:56 ET | 5275 | 7.24 |
09:57 ET | 790 | 7.22 |
09:59 ET | 1300 | 7.32 |
10:01 ET | 500 | 7.4199 |
10:03 ET | 500 | 7.3999 |
10:06 ET | 100 | 7.31 |
10:14 ET | 640 | 7.3 |
10:17 ET | 2189 | 7.35 |
10:19 ET | 200 | 7.35 |
10:21 ET | 963 | 7.34 |
10:24 ET | 6810 | 7.24 |
10:26 ET | 34299 | 7.27 |
10:30 ET | 300 | 7.28 |
10:33 ET | 200 | 7.3 |
10:37 ET | 152 | 7.311 |
10:42 ET | 100 | 7.32 |
10:48 ET | 100 | 7.33 |
10:53 ET | 200 | 7.38 |
10:55 ET | 1500 | 7.325 |
10:57 ET | 900 | 7.35 |
11:00 ET | 300 | 7.36 |
11:02 ET | 600 | 7.385 |
11:06 ET | 100 | 7.39 |
11:08 ET | 4664 | 7.36 |
11:11 ET | 2300 | 7.43 |
11:15 ET | 35915 | 7.49 |
11:18 ET | 15133 | 7.34 |
11:20 ET | 2638 | 7.345 |
11:22 ET | 46369 | 7.48 |
11:24 ET | 200 | 7.48 |
11:36 ET | 400 | 7.55 |
11:44 ET | 200 | 7.53 |
11:45 ET | 1700 | 7.5 |
11:47 ET | 1960 | 7.45 |
11:49 ET | 100 | 7.465 |
11:56 ET | 100 | 7.47 |
12:03 ET | 860 | 7.52 |
12:07 ET | 5324 | 7.4508 |
12:09 ET | 1200 | 7.47 |
12:14 ET | 100 | 7.49 |
12:21 ET | 108 | 7.480188 |
12:23 ET | 200 | 7.46 |
12:27 ET | 500 | 7.45 |
12:41 ET | 100 | 7.46 |
12:43 ET | 200 | 7.47 |
12:54 ET | 100 | 7.49 |
12:56 ET | 947 | 7.485 |
12:59 ET | 100 | 7.515 |
01:01 ET | 200 | 7.5 |
01:03 ET | 853 | 7.4975 |
01:06 ET | 400 | 7.5 |
01:08 ET | 400 | 7.49 |
01:10 ET | 100 | 7.515 |
01:14 ET | 200 | 7.52 |
01:17 ET | 850 | 7.5283 |
01:19 ET | 700 | 7.54 |
01:26 ET | 300 | 7.55 |
01:28 ET | 600 | 7.57 |
01:30 ET | 533 | 7.56 |
01:32 ET | 300 | 7.545 |
01:33 ET | 100 | 7.54 |
01:35 ET | 100 | 7.53 |
01:39 ET | 700 | 7.51 |
01:42 ET | 400 | 7.53 |
01:46 ET | 500 | 7.52 |
01:48 ET | 708 | 7.525 |
01:50 ET | 600 | 7.5158 |
01:51 ET | 300 | 7.53 |
01:57 ET | 100 | 7.53 |
02:00 ET | 200 | 7.535 |
02:08 ET | 100 | 7.52 |
02:09 ET | 100 | 7.54 |
02:15 ET | 500 | 7.58 |
02:18 ET | 100 | 7.56 |
02:20 ET | 400 | 7.56 |
02:22 ET | 400 | 7.545 |
02:24 ET | 100 | 7.55 |
02:27 ET | 100 | 7.53 |
02:29 ET | 745 | 7.56 |
02:33 ET | 109 | 7.555 |
02:38 ET | 800 | 7.56 |
02:42 ET | 100 | 7.55 |
02:44 ET | 1300 | 7.61 |
02:47 ET | 688 | 7.615 |
02:51 ET | 300 | 7.63 |
02:58 ET | 743 | 7.62 |
03:00 ET | 700 | 7.64 |
03:02 ET | 330 | 7.645 |
03:03 ET | 200 | 7.63 |
03:07 ET | 500 | 7.65 |
03:09 ET | 5791 | 7.63 |
03:12 ET | 200 | 7.6649 |
03:14 ET | 688 | 7.62 |
03:16 ET | 100 | 7.61 |
03:18 ET | 22580 | 7.52 |
03:20 ET | 1570 | 7.56 |
03:23 ET | 1700 | 7.62 |
03:25 ET | 200 | 7.66 |
03:27 ET | 1059 | 7.645 |
03:30 ET | 1100 | 7.61 |
03:32 ET | 100 | 7.6 |
03:34 ET | 711 | 7.61 |
03:36 ET | 1200 | 7.56 |
03:38 ET | 400 | 7.57 |
03:39 ET | 1398 | 7.55 |
03:41 ET | 4652 | 7.55 |
03:43 ET | 1402 | 7.55 |
03:45 ET | 127 | 7.5401 |
03:48 ET | 15691 | 7.5 |
03:50 ET | 900 | 7.5 |
03:52 ET | 600 | 7.49 |
03:54 ET | 400 | 7.49 |
03:56 ET | 569 | 7.47 |
03:57 ET | 2100 | 7.52 |
03:59 ET | 40761 | 7.53 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 156.6M | -0.9x | --- |
Generation Bio Co | 165.5M | -1.0x | --- |
Inovio Pharmaceuticals Inc | 144.1M | -1.1x | --- |
Ventyx Biosciences Inc | 148.4M | -0.8x | --- |
Century Therapeutics Inc | 131.3M | -0.8x | --- |
Actuate Therapeutics Inc | 145.7M | 0.0x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $156.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.01 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.